Hologic (HOLX) : Graybill Bartz Assoc Ltd scooped up 485 additional shares in Hologic during the most recent quarter end , according to a recent disclosure to the SEC on Apr 5, 2016. The investment management firm now holds a total of 58,615 shares of Hologic which is valued at $2.1 Million.Hologic makes up approximately 1.88% of Graybill Bartz Assoc Ltd’s portfolio.
Other Hedge Funds, Including , Curbstone Financial Management Corp boosted its stake in HOLX in the latest quarter, The investment management firm added 700 additional shares and now holds a total of 14,506 shares of Hologic which is valued at $508,000. Hologic makes up approx 0.17% of Curbstone Financial Management Corp’s portfolio.
On the company’s financial health, Hologic reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jan 27, 2016. Analyst had a consensus of $0.42. The company had revenue of $695.20 million for the quarter, compared to analysts expectations of $688.80 million. The company’s revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.
Many Wall Street Analysts have commented on Hologic. Needham Upgraded Hologic on Jan 28, 2016 to ” Buy”, Price Target of the shares are set at $41.Company shares were Reiterated by Barclays on Jan 7, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 42 from a previous price target of $40 .
Hologic closed down -0.35 points or -0.99% at $35.02 with 21,17,416 shares getting traded on Monday. Post opening the session at $35.5, the shares hit an intraday low of $34.95 and an intraday high of $35.71 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Companys business units are focused on diagnostics breast health GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.